Factors XI and XII as Targets for New Anticoagulants

Overview of attention for article published in Frontiers in Medicine, February 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (70th percentile)
Good Attention Score compared to outputs of the same age and source (76th percentile)

Mentioned by

twitter: 8 X users

facebook: 2 Facebook pages

Citations

dimensions_citation: 86 Dimensions

Readers on

mendeley: 105 Mendeley

Summary X Facebook Dimensions citations

So far, Altmetric has seen 11 X posts from 8 X users, with an upper bound of 8,831 followers.

@RNAiAnalyst $ions I don't see any competition from RNAi companies for FXI and FXII! FXII is wholly owned and uses LICA+2.5 tech. Interesting read on FXI and FXII: https://t.co/lo8BTR9BEY

17 Nov 2021

Reply Repost Favourite

$ions "... whether FXI or FXII is the better target and to compare the efficacy and safety of these new strategies with current standards of care for prevention or treatment of thrombosis." https://t.co/CrxVUgIujg https://t.co/Pvuj4VOf67

10 Aug 2021

Reply Repost Favourite

I don't believe management disclosed much about ph 2 factor XI data. Here is some interesting data. $ions https://t.co/lo8BTR9BEY https://t.co/IirwVodsms

09 Aug 2021

Reply Repost Favourite

RT @SEDENenf: "Factors XI and XII as Targets for New Anticoagulants" https://t.co/l2J59znm1L https://t.co/ccqnJn0kiO

28 Apr 2018

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 7 additional X posts.